JPWO2022102634A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022102634A5
JPWO2022102634A5 JP2022561950A JP2022561950A JPWO2022102634A5 JP WO2022102634 A5 JPWO2022102634 A5 JP WO2022102634A5 JP 2022561950 A JP2022561950 A JP 2022561950A JP 2022561950 A JP2022561950 A JP 2022561950A JP WO2022102634 A5 JPWO2022102634 A5 JP WO2022102634A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
pharmaceutical composition
composition according
drug conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561950A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022102634A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/041255 external-priority patent/WO2022102634A1/ja
Publication of JPWO2022102634A1 publication Critical patent/JPWO2022102634A1/ja
Publication of JPWO2022102634A5 publication Critical patent/JPWO2022102634A5/ja
Pending legal-status Critical Current

Links

JP2022561950A 2020-11-11 2021-11-10 Pending JPWO2022102634A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020188084 2020-11-11
PCT/JP2021/041255 WO2022102634A1 (ja) 2020-11-11 2021-11-10 抗体-薬物コンジュゲートと抗SIRPα抗体の組み合わせ

Publications (2)

Publication Number Publication Date
JPWO2022102634A1 JPWO2022102634A1 (https=) 2022-05-19
JPWO2022102634A5 true JPWO2022102634A5 (https=) 2024-11-18

Family

ID=81602324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561950A Pending JPWO2022102634A1 (https=) 2020-11-11 2021-11-10

Country Status (11)

Country Link
US (1) US20230414778A1 (https=)
EP (1) EP4245321A4 (https=)
JP (1) JPWO2022102634A1 (https=)
KR (1) KR20230106645A (https=)
CN (1) CN116916919A (https=)
AU (1) AU2021378152A1 (https=)
BR (1) BR112023008845A2 (https=)
CA (1) CA3198330A1 (https=)
IL (1) IL302812A (https=)
TW (1) TW202227140A (https=)
WO (1) WO2022102634A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250282865A1 (en) * 2022-05-10 2025-09-11 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-SIRPa ANTIBODY
CN119255825A (zh) * 2022-05-24 2025-01-03 第一三共株式会社 抗-cdh6抗体-药物缀合物的剂量方案
WO2025002310A1 (zh) * 2023-06-29 2025-01-02 石药集团巨石生物制药有限公司 抗体-药物偶联物及其用途
CN119454937A (zh) * 2023-11-13 2025-02-18 苏州宜联生物医药有限公司 抗b7h3抗体-药物偶联物治疗癌症的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
KR101598229B1 (ko) 2007-02-16 2016-02-26 메리맥 파마슈티컬즈, 인크. Erbb3에 대한 항체 및 이의 용도
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
IN2014DN06806A (https=) 2012-02-10 2015-05-22 Univ Maryland
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
AU2014371934B2 (en) 2013-12-25 2020-01-23 Daiichi Sankyo Company, Limited Anti-TROP2 antibody-drug conjugate
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
JP2017114763A (ja) 2014-03-26 2017-06-29 第一三共株式会社 抗cd98抗体−薬物コンジュゲート
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
BR112018070823A2 (pt) 2016-04-14 2019-02-05 Ose Immunotherapeutics anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
CN109862910A (zh) 2016-08-03 2019-06-07 小利兰·斯坦福大学托管委员会 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗gpr20抗体及び抗gpr20抗体−薬物コンジュゲート
KR102702926B1 (ko) 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體-藥物結合物及其用途
IL324591A (en) * 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods
JPWO2019044974A1 (ja) * 2017-08-31 2020-12-03 株式会社Veritas In Silico スモールガイドアンチセンス核酸とその使用
SG11202010496WA (en) * 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
SG11202012338QA (en) * 2018-07-10 2021-01-28 Univ Kobe Nat Univ Corp ANTI-SIRPa ANTIBODY
SG11202100653YA (en) * 2018-07-25 2021-02-25 Daiichi Sankyo Co Ltd Effective method for manufacturing antibody-drug conjugate
JP2022512541A (ja) * 2018-08-29 2022-02-07 シャタック ラボ,インコーポレイテッド Pd-1系キメラタンパク質を含む併用療法
JP7451520B2 (ja) * 2018-11-15 2024-03-18 ビョンディス・ビー.ブイ. ヒト化抗SIRPα抗体

Similar Documents

Publication Publication Date Title
JPWO2022102634A5 (https=)
TWI843705B (zh) 結晶及其改良製造方法、以及抗體-藥物結合物之改良製造方法
JPWO2020031936A5 (https=)
TWI868726B (zh) 抗體-藥物結合物之新穎製造方法
JP2025041725A5 (https=)
JPWO2020122034A5 (https=)
TWI865337B (zh) 抗體-藥物結合物之有效的製造方法
JP2020515578A5 (https=)
US20210252006A1 (en) Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof
JP2022093564A5 (https=)
ES2438495T3 (es) Compuestos para exterminar células cancerosas que expresan PSMA, resistentes a taxano
CA3047359A1 (en) Hdac inhibitors-based antibody drug conjugates (adcs) and use in therapy
TW202019487A (zh) 抗體-藥物結合物及微管蛋白抑制劑之組合
JPWO2019230645A5 (https=)
JP2018537975A5 (https=)
JP2017521090A5 (https=)
TWI822740B (zh) 抗her2雙互補位抗體-藥物結合物及使用方法
JP2010535713A5 (https=)
JP2008546792A5 (https=)
WO2015165413A1 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
JP2015500287A (ja) 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法
JPWO2020027100A5 (https=)
JP2010508847A5 (https=)
RU2007135167A (ru) Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака
IL302812A (en) Antibody-drug conjugate combinations with anti-SIRP alpha antibody